The roles of patents and research and development incentives in biopharmaceutical innovation.
Repository Usage Stats
Patents and other forms of intellectual property protection play essential roles in encouraging innovation in biopharmaceuticals. As part of the "21st Century Cures" initiative, Congress is reviewing the policy mechanisms designed to accelerate the discovery, development, and delivery of new treatments. Debate continues about how best to balance patent and intellectual property incentives to encourage innovation, on the one hand, and generic utilization and price competition, on the other hand. We review the current framework for accomplishing these dual objectives and the important role of patents and regulatory exclusivity (together, the patent-based system), given the lengthy, costly, and risky biopharmaceutical research and development process. We summarize existing targeted incentives, such as for orphan drugs and neglected diseases, and we consider the pros and cons of proposed voluntary or mandatory alternatives to the patent-based system, such as prizes and government research and development contracting. We conclude that patents and regulatory exclusivity provisions are likely to remain the core approach to providing incentives for biopharmaceutical research and development. However, prizes and other voluntary supplements could play a useful role in addressing unmet needs and gaps in specific circumstances.
Awards and Prizes
Orphan Drug Production
Patents as Topic
Published Version (Please cite this version)10.1377/hlthaff.2014.1047
Publication InfoDiMasi, Joseph A; Grabowski, Henry G; & Long, Genia (2015). The roles of patents and research and development incentives in biopharmaceutical innovation. Health Aff (Millwood), 34(2). pp. 302-310. 10.1377/hlthaff.2014.1047. Retrieved from http://hdl.handle.net/10161/12744.
This is constructed from limited available data and may be imprecise. To cite this article, please review & use the official citation provided by the journal.
More InfoShow full item record
Professor Emeritus of Economics
Professor Grabowski specializes in the investigation of economics in the pharmaceutical industry, government regulation of business, and the economics of innovation. His specific interests within these fields include intellectual property and generic competition issues, the effects of government policy actions, and the costs and returns to pharmaceutical R&D. He has been publishing research papers for over four decades, from his earlier work, “The Effects of Regulatory Policy on the Incentives
Professor of Medicine
1. High dose therapy and autologous and allogeneic stem cell rescue for hematologic malignancies (especially multiple myeloma) and solid tumors. 2. Non-myeloablative allogeneic transplants for hematologic malignancies and solid tumors. 3. Supportive care for hematopoietic stem cell transplants. 4. Prevention and therapy of graft versus host disease.
Alphabetical list of authors with Scholars@Duke profiles.